

GP1615  
RECEIVED  
OCT 25 2000



APPLICANTS : Smith et al.  
INVENTION : PRODUCTION OF POROUS ARTICLES  
ATTORNEYS : Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.  
SERIAL NO. : 09/269,999  
FILED : June 28, 1999  
GROUP : 1615  
EXAMINER : Todd D. Ware

TECH CENTER 1600/2800

#7  
HKO  
10/25/00


RECEIVED  
OCT 20 2000  
TECHNOLOGY CENTER 1700

This is a Response to Restriction Requirement which includes the following:

1. Transmittal letter
2. Response to Restriction Requirement
3. Return Receipt Postcard

CERTIFICATE OF MAILING

I hereby certify that the foregoing Response to Restriction Requirement, re:  
Application Serial No. 09/269,999 is being deposited with the United States Postal  
Service and First Class Mail, postage prepaid, in an envelope addressed to  
Commissioner for Patents, Washington, D.C., 20231 on this 17<sup>th</sup> day of October, 2000.

  
\_\_\_\_\_  
Gary A. Greene

S1011 20102



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING DIVISION

RECEIVED

OCT 25 2000

TECH CENTER 1600/2900

APPLICANTS : Smith et al.  
INVENTION : PRODUCTION OF POROUS ARTICLES  
ATTORNEYS : Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.  
SERIAL NO. : 09/269,999  
FILED : June 28, 1999  
GROUP : 1615  
EXAMINER : Todd D. Ware

Response to Restriction Requirement

Commissioner for Patents  
Washington, DC 20231

Sir:

In an Office Action dated September 25, 2000, a Restriction Requirement was made under 35 U.S.D. §§121 and 372. The Examiner states that the applicant must elect a single invention of one of Group I directed to claims 11-18 drawn to a method of making a ceramic article, Group II directed to claim 19 drawn to a method of growing bone cells in a ceramic product, or Group III directed to claim 20 drawn to method of adding a drug to the pores of a ceramic article. The Examiner states that Groups I, II, and III, do not relate to a single general inventive concept because Group I does not require ingredients for orthopedic or surgical use nor does it require a pharmaceutical agent.

Group I (claims 11-18) is provisionally elected with traverse. All of claims 12 through 20 depend either directly or indirectly from claim 11, including claims 19 and 20. For the sake of efficiency for both the Patent Office and the applicants, applicants respectfully request that the restriction requirement be withdrawn.

RECEIVED  
OCT 20 2000  
TECHNOLOGY CENTER 1700

Based on the above election and traverse, applicants respectfully request an Office Action on the merits of this application.




Date: October 17, 2000

RECEIVED

OCT 25 2000

TECH CENTER 1600/2900

Respectfully submitted,  
CAESAR, RIVISE, BERNSTEIN  
COHEN & POKOTILOW, LTD.

By 

Gary A. Greene  
Registration No. 38,897  
Seven Penn Center - 12<sup>th</sup> Floor  
1635 Market Street  
Philadelphia, PA 19103-2212  
(215)567-2010  
Attorney for Applicant

RECEIVED  
OCT 20 2000  
TECHNOLOGY CENTER 1700